Tumor organoids in cancer medicine: from model systems to natural compound screening
Context The advent of tissue engineering and biomedical techniques has significantly advanced the development of three-dimensional (3D) cell culture systems, particularly tumor organoids. These self-assembled 3D cell clusters closely replicate the histopathological, genetic, and phenotypic character...
Saved in:
| Main Authors: | , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | Pharmaceutical Biology |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/13880209.2025.2458149 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1832572870862045184 |
|---|---|
| author | Rong Cong Can Lu Xinying Li Zhijie Xu Yaqin Wang Shusen Sun |
| author_facet | Rong Cong Can Lu Xinying Li Zhijie Xu Yaqin Wang Shusen Sun |
| author_sort | Rong Cong |
| collection | DOAJ |
| description | Context The advent of tissue engineering and biomedical techniques has significantly advanced the development of three-dimensional (3D) cell culture systems, particularly tumor organoids. These self-assembled 3D cell clusters closely replicate the histopathological, genetic, and phenotypic characteristics of primary tissues, making them invaluable tools in cancer research and drug screening.Objective This review addresses the challenges in developing in vitro models that accurately reflect tumor heterogeneity and explores the application of tumor organoids in cancer research, with a specific focus on the screening of natural products for antitumor therapies.Methods This review synthesizes information from major databases, including Chemical Abstracts, Medicinal and Aromatic Plants Abstracts, ScienceDirect, Google Scholar, Scopus, PubMed and Springer Link. Publications were selected without date restrictions, using terms such as ‘organoid’, ‘natural product’, ‘pharmacological’, ‘extract’, ‘nanomaterial’ and ‘traditional uses’. Articles related to agriculture, ecology, synthetic work or published in languages other than English were excluded.Results and conclusions The review identifies key challenges related to the efficiency and variability of organoid generation and discusses ongoing efforts to enhance their predictive capabilities in drug screening and personalized medicine. Recent studies utilizing patient-derived organoid models for natural compound screening are highlighted, demonstrating the potential of these models in developing new classes of anticancer agents. The integration of natural products with patient-derived organoid models presents a promising approach for discovering novel anticancer compounds and elucidating their mechanisms of action. |
| format | Article |
| id | doaj-art-44b8dd1b063f4c4694ba8871428ecb25 |
| institution | Kabale University |
| issn | 1388-0209 1744-5116 |
| language | English |
| publishDate | 2025-12-01 |
| publisher | Taylor & Francis Group |
| record_format | Article |
| series | Pharmaceutical Biology |
| spelling | doaj-art-44b8dd1b063f4c4694ba8871428ecb252025-02-02T06:24:55ZengTaylor & Francis GroupPharmaceutical Biology1388-02091744-51162025-12-016318910910.1080/13880209.2025.2458149Tumor organoids in cancer medicine: from model systems to natural compound screeningRong Cong0Can Lu1Xinying Li2Zhijie Xu3Yaqin Wang4Shusen Sun5Department of General Surgery, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Pathology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of General Surgery, Xiangya Hospital, Central South University, Changsha, ChinaDepartment of Pathology, National Clinical Research Center for Geriatric Disorders, Xiangya Hospital, Central South University, Changsha, ChinaClinical Research Center for Reproduction and Genetics in Hunan Province, Reproductive and Genetic Hospital of CITIC-Xiangya, Changsha, ChinaCollege of Pharmacy and Health Sciences, Western New England University, Springfield, MA, USAContext The advent of tissue engineering and biomedical techniques has significantly advanced the development of three-dimensional (3D) cell culture systems, particularly tumor organoids. These self-assembled 3D cell clusters closely replicate the histopathological, genetic, and phenotypic characteristics of primary tissues, making them invaluable tools in cancer research and drug screening.Objective This review addresses the challenges in developing in vitro models that accurately reflect tumor heterogeneity and explores the application of tumor organoids in cancer research, with a specific focus on the screening of natural products for antitumor therapies.Methods This review synthesizes information from major databases, including Chemical Abstracts, Medicinal and Aromatic Plants Abstracts, ScienceDirect, Google Scholar, Scopus, PubMed and Springer Link. Publications were selected without date restrictions, using terms such as ‘organoid’, ‘natural product’, ‘pharmacological’, ‘extract’, ‘nanomaterial’ and ‘traditional uses’. Articles related to agriculture, ecology, synthetic work or published in languages other than English were excluded.Results and conclusions The review identifies key challenges related to the efficiency and variability of organoid generation and discusses ongoing efforts to enhance their predictive capabilities in drug screening and personalized medicine. Recent studies utilizing patient-derived organoid models for natural compound screening are highlighted, demonstrating the potential of these models in developing new classes of anticancer agents. The integration of natural products with patient-derived organoid models presents a promising approach for discovering novel anticancer compounds and elucidating their mechanisms of action.https://www.tandfonline.com/doi/10.1080/13880209.2025.2458149Cancerorganoidsnatural productsnanomaterial |
| spellingShingle | Rong Cong Can Lu Xinying Li Zhijie Xu Yaqin Wang Shusen Sun Tumor organoids in cancer medicine: from model systems to natural compound screening Pharmaceutical Biology Cancer organoids natural products nanomaterial |
| title | Tumor organoids in cancer medicine: from model systems to natural compound screening |
| title_full | Tumor organoids in cancer medicine: from model systems to natural compound screening |
| title_fullStr | Tumor organoids in cancer medicine: from model systems to natural compound screening |
| title_full_unstemmed | Tumor organoids in cancer medicine: from model systems to natural compound screening |
| title_short | Tumor organoids in cancer medicine: from model systems to natural compound screening |
| title_sort | tumor organoids in cancer medicine from model systems to natural compound screening |
| topic | Cancer organoids natural products nanomaterial |
| url | https://www.tandfonline.com/doi/10.1080/13880209.2025.2458149 |
| work_keys_str_mv | AT rongcong tumororganoidsincancermedicinefrommodelsystemstonaturalcompoundscreening AT canlu tumororganoidsincancermedicinefrommodelsystemstonaturalcompoundscreening AT xinyingli tumororganoidsincancermedicinefrommodelsystemstonaturalcompoundscreening AT zhijiexu tumororganoidsincancermedicinefrommodelsystemstonaturalcompoundscreening AT yaqinwang tumororganoidsincancermedicinefrommodelsystemstonaturalcompoundscreening AT shusensun tumororganoidsincancermedicinefrommodelsystemstonaturalcompoundscreening |